Example: Heart Attack

Clinical Trials on Immune Complex Diseases

Total 97 results

    • NCT03277703
      Recruiting
      Flu Vaccine Response in Patients on Biologic Therapies
      Conditions: Rheumatologic Disorder; Inflammatory Bowel Diseases; Immune Complex Diseases
    • NCT02741362
      Terminated
      Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome
      Conditions: Systemic Lupus Erythematosus; Rheumatoid Arthritis; Sharp's Syndrome
    • NCT03340155
      Recruiting
      Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
      Conditions: Psoriasis; Cutaneous T Cell Lymphoma; Lymphoproliferative Disorders; Eczema; Lichen Planus; Prurigo; Pruritus; Polymorphic Light Eruption; Graft Vs Host Disease; Mastocytosis; Vitiligo
    • NCT04615663
      Recruiting
      Assessment of Burden Disease in Patients With Mast Cell Disorders
      Conditions: Mastocytosis; Cutaneous
    • NCT02450396
      Unknown status
      Pregnancy and Medically Assisted Conception in Rare Diseases
      Conditions: Rheumatoid Arthritis; Spondyloarthritis; Psoriatic Arthritis; Systemic Lupus Erythematosus; Antiphospholipid Syndrome; Sjogren Syndrome; Scleroderma; Myositis; Vasculitis; Mastocytosis; Various Autoimmune and/or Systemic and/or Rare Diseases
    • NCT03406325
      Completed
      Mast Cell Activation Test in Allergic Disease
      Conditions: Asthma; Mastocytosis; Mast Cell Activation Syndrome; Food Allergy; Chronic Idiopathic Urticaria; Anaphylaxis; Eczema
    • NCT03591471
      Unknown status
      Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment
      Conditions: Henoch-Schönlein Purpura Nephritis
    • NCT00769587
      Completed
      Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
      Conditions: Non Neoplastic Condition; Precancerous Condition
    • NCT02561988
      Active, not recruiting
      (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
      Conditions: Aggressive Systemic Mastocytosis; Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease; Mast Cell Leukemia; Relapsed or Refractory Myeloid Malignancies
    • NCT04377828
      Recruiting
      Improvement of Pigmented Skin Lesions in Patients With Mastocytosis After Performing 2 Sessions of Pigment Laser
      Conditions: Cutaneous Mastocytosis
    • NCT01807598
      Completed
      Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
      Conditions: Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic Mastocytosis
    • NCT02760238
      Recruiting
      Myeloproliferative Neoplasms (MPNs) Patient Registry
      Conditions: Primary Myelofibrosis; Polycythemia Vera; Essential Thrombocythemia; Mastocytosis; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Juvenile; Chronic Eosinophilic Leukemia-not Otherwise Specified; Myelodysplastic-Myeloproliferative Diseases; Neoplasms; Leukemia, Myelomonocytic, Chronic
    • NCT04681105
      Recruiting
      Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
      Conditions: Recurrent Acute Leukemia; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hairy Cell Leukemia; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent T Acute Lymphoblastic Leukemia; Refractory Acute Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Hairy Cell Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory T Acute Lymphoblastic Leukemia; Systemic Mastocytosis
    • NCT00557895
      Terminated
      Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
      Conditions: Allergy; Asthma; Allergic Rhinitis; Mastocytosis; Atopic Dermatitis; Food Allergy
    • NCT04714086
      Available
      Expanded Access Program (EAP) for Avapritinib in Patients With AdvSM
      Conditions: Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematological Neoplasm; Mast Cell Leukemia
    • NCT04695431
      Enrolling by invitation
      Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
      Conditions: Advanced Systemic Mastocytosis; Aggressive Systemic Mastocytosis; Systemic Mastocytosis With an Associated Hematological Neoplasm; Mast Cell Leukemia
    • NCT03410290
      Completed
      Journey of Patients With Vasculitis From First Symptom to Diagnosis
      Conditions: Vasculitis; Systemic Vasculitis; Behcet's Disease; CNS Vasculitis; Cryoglobulinemic Vasculitis; Eosinophilic Granulomatous Vasculitis; Temporal Arteritis; Giant Cell Arteritis; Granulomatosis With Polyangiitis; Wegener Granulomatosis; Henoch Schonlein Purpura; IgA Vasculitis; Microscopic Polyangiitis; Polyarteritis Nodosa; Takayasu Arteritis; Urticarial Vasculitis
    • NCT02380222
      Completed
      Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
      Conditions: Aggressive Systemic Mastocytosis (ASM); SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD); Mast Cell Leukemia (MCL); Smoldering Systemic Mastocytosis (SSM); Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited
    • NCT04333108
      Recruiting
      Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
      Conditions: Indolent Systemic Mastocytosis
    • NCT02550080
      Unknown status
      Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
      Conditions: Allergic Cutaneous Vasculitis; Urticaria; Psoriasis; Acne; Bullous Skin Diseases; Sterile Pustulosis; Leprosy; Pneumocystis Pneumonia
    • NCT04655378
      Enrolling by invitation
      Validation of the IgA1 Detection Method With Gradient Glycosylation by Mass Spectrometry as a Potential Marker of Renal Involvement in Pediatric Rheumatoid Purpura
      Conditions: Rheumatoid Purpura; Pediatric ALL
    • NCT04623866
      Not yet recruiting
      Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules
      Conditions: Henoch Schönlein Purpura Nephritis
    • NCT03739606
      Withdrawn
      Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
      Conditions: Acute Biphenotypic Leukemia; Acute Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hairy Cell Leukemia; Interleukin-3 Receptor Subunit Alpha Positive; Recurrent Acute Lymphoblastic Leukemia; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Systemic Mastocytosis
    • NCT04387942
      Recruiting
      The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura
      Conditions: Purpura, Schoenlein-Henoch
    • NCT03770273
      Recruiting
      Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
      Conditions: Indolent Systemic Mastocytosis
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations